FDA — authorised 29 October 2019
- Application: NDA211855
- Marketing authorisation holder: BIOGEN INC
- Status: supplemented
FDA authorised Vumerity on 29 October 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 29 October 2019; FDA has authorised it.
BIOGEN INC holds the US marketing authorisation.